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Abstract
Background: Glycochenodeoxycholate (GCDA) is one of the major human bile salts. Bile salts stimulate cell survival
and proliferation through the mitogen-activated protein kinase, but the downstream signaling mechanism(s)
remains enigmatic. Mcl-1 is an antiapoptotic molecule of the Bcl2 family that is extensively overexpressed in tumor
tissues of patients with hepatocellular carcinoma (HCC).
Results: Here we found that exposure of HepG2 cells to GCDA results in activation of ERK1 and ERK2 and
phosphorylation of Mcl-1 in a PD98059 (MEK inhibitor)-sensitive manner. GCDA stimulates Mcl-1 phosphorylation in
cells expressing WT but not T163A Mcl-1 mutant, indicating that GCDA-induced Mcl-1 phosphorylation occurs
exclusively at the T163 site in its PEST region. GCDA-induced Mcl-1 phosphorylation at T163 enhances the half-life
of Mcl-1. Treatment of HepG2 cells with GCDA facilitates Mcl-1 dissociation from Mule (a physiological Mcl-1
ubiquitin E3 ligase). Specific depletion of Mcl-1 from HepG2 cells by RNA interference increases sensitivity of
HepG2 cells to chemotherapeutic drugs (i.e. cisplatin and irinotecan). In addition to activation of the ERK/Mcl-1
survival pathway, GCDA can also induce dose-dependent apurinic/apyrimidinic (AP) sites of DNA lesions, which
may partially neutralize its survival activity.
Conclusion: Our findings suggest that bile salt may function as a survival agonist and/or potential carcinogen in
the development of HCC. Molecular approaches that inactivate Mcl-1 by blocking its T163 phosphorylation may
represent new strategies for treatment of HCC.
Background
Hepatocellular carcinoma (HCC) is the 5th most com-
mon cancer worldwide with approximately 564,000 new
cases diagnosed every year [1]. Patients with HCC have
poor prognosis, with few treatment options available [2].
Therefore, the development of novel strategies by identi-
fying key targets at a molecular level is critical to cure
HCC. Recent studies suggest that the aggressiveness,
responsiveness to therapy and prognosis of HCC are
closely linked to the Bcl-2 family members [1,3].
The Bcl2 family members have homology clustered
within four conserved Bcl2 homology (BH) domains:
BH1, BH2, BH3 and BH4, with only the antiapoptotic
proteins, Bcl2, Bcl-XL, Bcl-w and A1, bearing the NH2-
terminal BH4 domain [4]. In contrast, Mcl-1 has a heli-
cal BH4-like domain which is located between the PEST
region and the BH3 domain [5]. The proapoptotic
family members can be divided into two subgroups
based on the presence of BH domains: the BH123 multi-
domain proteins (i.e. Bax and Bak) and the BH3-only
molecules [6-8]. Recent studies suggest that there are
two different subgroups in the BH3-only members. One
group, including Bid and Bim, can function both directly
to bind and activate Bax as well as indirectly to counter-
act the inhibition of Bax or Bak by antiapoptotic mem-
bers including Bcl2 and Bcl-XL. Other BH3-only
proteins (i.e. Bad, Bik, Noxa and PUMA) lack the ability
to directly activate Bax but can oppose the action of
antiapoptotic family members. Thus, both direct and
indirect functions of BH3-only proteins may initiate
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apoptosis via selective interaction of its BH3 domain
with an extended hydrophobic groove on the antiapop-
totic Bcl2-like proteins and/or facilitate a conformational
change in the multidomain proapoptotic proteins (i.e.
Bax and Bak), which induce a death effect by promoting
their insertion into mitochondrial membranes and oligo-
merization [6-8]. Bcl2 and related antiapoptotic proteins
block the progression of a death signal by preventing
Bax/Bak oligomerization [9].
Mcl-1 is a major antiapoptotic member of the Bcl2
family, which is crucial for liver development and hepa-
tocellular homeostasis [10,11]. Mcl-1 is also an oncopro-
tein that promotes the development of cancer [12,13].
Importantly, Mcl-1 is overexpressed in about 50% of
HCC patients [1], suggesting that Mcl-1 is a potential
therapeutic target for some patients with HCC. In con-
trast to Bcl2 and Bcl-XL, Mcl-1 is rapidly inducible with
a shorter half-life and seems to be more widely
expressed in HCC [1,9,14]. Mcl-1 is mainly localized to
the outer mitochondrial membrane via its C-terminal
TM domain [15,16]. Several residues, including serine
(S) 64, threonine (T) 92, S155, S159 and T163, have
been identified as the potential phosphorylation sites fol-
lowing various stimuli [15,17-19]. However, phosphory-
lation of Mcl-1 at different site(s) distinctly regulates
Mcl-1 protein turnover and its anti-apoptotic function
[17-19]. For example, ERK1/2-mediated T163 site phos-
phorylation of Mcl-1 prolongs the half-life of Mcl-1,
which leads to its increased antiapoptotic function
[12,18]. We have recently discovered that nicotine
induces Mcl-1 phosphorylation at T163 in association
with increased chemoresistance of human lung cancer
cells [20]. In contrast, GSK-3b-mediated Mcl-1 phos-
phorylation at the S159 site facilitates Mcl-1 ubiquitina-
tion and degradation leading to decreased survival
activity [19]. It has been suggested that the BH3-only
protein Bim can directly activate Bak, leading to mito-
chondrial dysfunction and apoptosis [6]. Thus, Mcl-1
may exert its antiapoptotic function via direct interac-
tion with Bim leading to suppression of Bim-triggered
Bak activation.
Bile is produced by the liver and consists of phospholi-
pids and bile salts forming mixed micelles. Bile salts con-
stitute a major portion of bile and are secreted by
hepatocytes into the canaliculi. Hepatocellular bile salt
secretion is mediated by an ATP-binding cassette (ABC)
transporter named bile salt export pump (BSEP), which
drives and maintains enterohepatic circulation of bile
salts [21]. Bile salts have carcinogenic roles because bile
salts not only induce DNA damage but also stimulate cell
survival and proliferation [22-25]. Thus, accumulation of
bile salts or bile acids in hepatocytes by some mechan-
isms may lead to chronic liver damage, proliferation or
development of HCC [24-26]. Bile acid (i.e. deoxycholate)
has been reported to enhance Mcl-1 expression through
activation of the EGFR/Raf-1 signaling pathway in KMBC
cells (a human cholangiocarcinoma cell line), which may
participate in cholangiocyte carcinogenesis by inhibiting
apoptosis [26]. It is currently unclear whether bile salts
also regulate Mcl-1 in HCC cells through a similar or dis-
tinct mechanism(s).The conjugated bile salt, glycocheno-
deoxyocholic acid (GCDA), has been reported to activate
PI3K/AKT and MAPK ERK1/2 signaling pathways in
association with increased survival and proliferation of
SEG-1 cells (a Barrett’s adenoma cell line) [24,25]. How-
ever, the downstream survival substrate(s) is not yet iden-
tified. Here we demonstrate that GCDA-activated ERK1/
2 induces Mcl-1 phosphorylation at T163, which stabi-
lizes Mcl-1 protein to enhance its antiapoptotic function.
Additionally, GCDA can also induce apurinic/apyrimidi-
nic (AP) sites of DNA lesions. These properties of GCDA
may contribute to the development of HCC and/or
chemoresistance.
Results
GCDA induces activation of ERK1/2 and Mcl-1
phosphorylation leading to increased association with
Bim in HepG2 cells
Mcl-1 is a major antiapoptotic molecule of the Bcl2
family that is expressed in about 50% of HCC [1]. High
levels of endogenous Mcl-1 were also observed in var-
ious HCC cell lines (Figure 1A). Thus, Mcl-1 may play a
critical role in regulating survival and/or chemoresis-
tance of HCC. The bile salt GCDA has been reported to
activate ERK1/2 in SEG-1 cells [24]. To test whether
GCDA can also activate ERK1/2 in HCC cells, HepG2
cells were treated with GCDA (100 μM) for 30 min.
Phosphorylation of ERK1/2 was analyzed by Western
blot using a phospho-specific ERK antibody. Results
indicate that GCDA induces phosphorylation and activa-
tion of ERK1/2 in HepG2 cells in a dose-dependent
manner (Figure 1B). Since ERK1 and ERK2 are physiolo-
gic Mcl-1 kinases [18], GCDA-activated ERK1/2 may
phosphorylate Mcl-1 in HepG2 cells. To test this possi-
bility, HepG2 cells were metabolically labeled with 32P-
orthophosphoric acid and treated with GCDA in the
absence or presence of the MEK inhibitor PD98059 for
30 min. Results indicate that GCDA potently stimulates
phosphorylation of endogenous Mcl-1 in HepG2 cells
(Figure 1C). Importantly, inhibition of MEK/ERK by
PD98059 blocks GCDA-induced Mcl-1 phosphorylation
(Figure 1C). These findings suggest that GCDA-stimu-
lated Mcl-1 phosphorylation may occur through activa-
tion of ERK1/2, which may contribute to enhanced
chemoresistance. To test the effects of GCDA on ERK1/
2 and Mcl-1 in normal liver and other HCC cell lines,
similar experiments were carried out in L02, Bel-7402,
Huh7 and HepG2 cells. Results reveal that GCDA can
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also activate ERK/2 and induce Mcl-1 phosphorylation
in normal liver L02 cells and various types of HCC cells
(Additional file 1, Figure S1).
Mcl-1 is thought to inhibit apoptosis by sequestering
the proapoptotic BH3-only proteins (i.e. Bim) and/or
binding the proapoptotic, multidomain Bak [10]. To test
whether GCDA-induced Mcl-1 phosphorylation affects
its ability to associate with Bim, HepG2 cells were trea-
ted with increasing concentrations of GCDA. A co-
immunoprecipitation experiment was performed to
measure the Mcl-1/Bim interaction. Results reveal that
GCDA promotes Mcl-1 to associate with Bim in a dose-
dependent manner (Figure 2), which may suppress the
proapoptotic function of Bim to enhance survival and
chemoresistance of HCC cells.
GCDA stimulates Mcl-1 phosphorylation at T163 site in
association with increased chemoresistance
ERK1 and ERK2 have been reported to phosphorylate
Mcl-1 at T163 and enhance the antiapoptotic activity of
Mcl-1 [18]. Because GCDA can activate ERK1/2, it is
possible that GCDA may stimulate Mcl-1 phosphoryla-
tion at the T163 site. To test this, we have constructed
HA-tagged WT and the non-phosphorylatable T163A
Mcl-1 mutant. WT and the T163A Mcl-1 mutant were
overexpressed in Huh7 cells that express relatively low
levels of endogenous Mcl-1. Cells overexpressing HA-
tagged WT, T163A or vector-only control were metabo-
lically labeled with 32P-orthophosphoric acid and treated
with GCDA (100 μM) for 30 min. HA-tagged Mcl-1 was
immunoprecipitated using an HA antibody. Phosphory-
lation of exogenous HA-tagged Mcl-1 was analyzed by
autoradiography. The same filter was then probed by
Western blot using an HA antibody. Since GCDA
induces phosphorylation of WT but not T163A Mcl-1
mutant (Figure 3A), GCDA-stimulated Mcl-1phosphory-
lation may occur exclusively at the T163 site. Impor-
tantly, GCDA prolongs survival of cells expressing WT
but not the T163A Mcl-1 mutant following treatment
with cisplatin or irinotecan (Figure 3BC). These findings
provide genetic evidence that phosphorylation of Mcl-1
at T163 is essential for GCDA-induced survival of HCC
cells.
GCDA increases the half-life of Mcl-1 and disrupts its
interaction with E3 ligase Mule in HepG2 cells
Mcl-1 has a short-term pro-survival function due to its
short half-life. A previous report indicates that bile acids
can increase total cellular Mcl-1 protein levels in KMBC
cells, which is dependent upon activation of an EGFR/
Raf-1 cascade [26]. To test whether GCDA-stimulated
T163 phosphorylation of Mcl-1 affects its stability in
HCC cells, the half-life of Mcl-1 was measured using
cycloheximide blocking methods as described [27].
HepG2 cells were treated with 100 μg/ml cycloheximide
in the absence or presence of GCDA (100 μM) for var-
ious times as indicated. Results reveal that GCDA signif-
icantly prolongs the half-life of Mcl-1 (Figure 4A). To
Figure 1 GCDA activates ERK1/2 and induces Mcl-1
phosphorylation in HepG2 cells. (A) Expression of Mcl-1 in
various HCC cell lines and normal liver cell line L02 was analyzed by
Western blot. (B) HepG2 cells were treated with increasing
concentrations of GCDA for 30 min. Phosphorylation of ERK1/2 or
total ERK1/2 was analyzed by Western blot using phospho-specific
ERK or ERK1/2 antibodies, respectively. (C) HepG2 cells were
metabolically labeled with 32P-orthophosphoric acid for 60 min and
treated with GCDA (100 μM) in the absence or presence of
PD98059 (10 μM) for 30 min. Mcl-1 was immunoprecipitated by
using Mcl-1 antibody. Phosphorylation of Mcl-1 was determined by
autoradiography. Western blot analysis was performed to confirm
and quantify Mcl-1 protein. Ctrl, immunoprecipitation with normal
rabbit IgG as a negative control.
Figure 2 GCDA promotes Mcl-1/Bim interaction. HepG2 cells
were treated with increasing concentrations of GCDA for 24h. A co-
immunoprecipitation was performed using a Mcl-1 antibody. The
Mcl-1-associated Bim and Mcl-1 were analyzed by Western blot.
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more accurately evaluate the turnover rate of Mcl-1, we
also used the classical 35S-methionine pulse-chase
method as we previously described [28]. The 35S-
methionine-labeled cells were washed and incubated in
fresh methionine-replete RPMI medium 1640 in the
absence or presence of GCDA (100 μM) for various
times (i.e. 0 h, 0.5 h, 1 h, 2 h, 3 h and 6 h). The half-life
(t1/2) of Mcl-1 was determined by electronic autoradio-
graphy. Consistently, exposure of cells to GCDA
increases the half-life of Mcl-1 from 2.1 h to 8.2 h (Fig-
ure 4B). These data suggest that GCDA-prolonged half-
life of Mcl-1 may lead to a long-term survival activity.
Mule is a known Mcl-1 ubiquitin E3 ligase that can
directly interact with Mcl-1 to facilitate Mcl-1 ubiquiti-
nation and degradation [29]. To test whether GCDA-
induced Mcl-1 phosphorylation affects Mule/Mcl-1
association, HepG2 cells were treated with increasing
concentrations of GCDA for 30 min. A co-immunopre-
cipitation was performed using an Mcl-1 antibody. Intri-
guingly, treatment of cells with GCDA results in
dissociation of the Mule/Mcl-1 complex in a dose-
dependent manner (Figure 4C), which may prevent Mcl-
1 from Mule-mediated ubiquitination and degradation.
This helps explain why GCDA significantly prolongs the
half-life of Mcl-1 (Figure 4AB).
GCDA reverses irinotecan-induced downregulation of
pERK and Mcl-1 in association with prolonged survival of
HepG2 cells
Irinotecan is a topoisomerase-I inhibitor (i.e. camptothe-
cin derivative, CPT11) which has been used as one of
Figure 3 GCDA induces Mcl-1 phosphorylation at T163 site,
which is essential for GCDA-stimulated survival. (A) Huh7 cells
overexpressing exogenous HA-tagged WT, T163A Mcl-1 mutant or
vector-only control cells were metabolically labeled with 32P-
orthophosphoric acid and treated with GCDA for 30 min. Mcl-1 was
immunoprecipitated using an HA antibody. Phosphorylation of Mcl-
1 was determined by autoradiography. (B) and (C) Huh7 cells
expressing WT or T163A Mcl-1 mutant were treated with cisplatin
(30 μM) or irinotecan (40 μM) in the absence or presence of GCDA
(100 μM) for 48 h. Cell viability was determined by analyzing
annexin-V binding by FACS. Data represent the mean ± S.D. of
three separate determinations.
Figure 4 Treatment of cells with GCDA disrupts Mule/Mcl-1
interaction and prolongs the half-life of Mcl-1. (A) HepG2 cells
expressing high levels of endogenous Mcl-1 were treated with 100
μg/ml cycloheximide 5 min prior to starting the indicated time
course (i.e. 0 h, 0.5 h, 1 h, 2 h, 3 h, 6 h) in the absence or presence
of GCDA (100 μM). Mcl-1 was analyzed by Western blot. (B) HepG2
cells were metabolically labeled with 35S-methionine. A classic
pulse-chase experiment with the same time course as above (i.e. 0
h, 0.5 h, 1 h, 2 h, 3 h, 6 h) was carried out. The half-life of Mcl-1 was
determined by electronic autoradiography. (C) HepG2 cells were
treated with increasing concentrations of GCDA. A co-
immunoprecipitation was carried out using an Mcl-1 antibody. The
Mcl-1-associated Mule and Mcl-1 were analyzed by Western blot.
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the first-line chemotherapeutic drugs for treatment of
patients with advanced HCC [30,31]. Our findings indi-
cate that treatment of HepG2 cells with irinotecan
downregulates ERK phosphorylation in association with
decreased Mcl-1 expression (Figure 5AB). Intriguingly,
GCDA can reverse the negative effects of irinotecan on
pERK and Mcl-1 expression (Figure 5AB). To further
test whether GCDA affects the sensitivity of HepG2
cells to irinotecan, HepG2 cells were treated with irino-
tecan (i.e. 40 μM) in the absence or presence of GCDA
(i.e. 100 μM) for 24 h. Results reveal that GCDA pro-
longs survival of HepG2 cells following irinotecan treat-
ment, suggesting that GCDA may contribute to
chemoresistance during HCC treatment (Figure 5C).
GCDA induces AP sites of DNA lesions in HepG2 cells
Our findings show that GCDA can stimulate the survi-
val signaling pathway (i.e. GCDA/ERK/Mcl-1). In addi-
tion to the ERK/Mcl-1 survival pathway, we also tested
the effect of GCDA on DNA damage. HepG2 cells were
treated with increasing concentrations of GCDA for 60
min. DNA damage was analyzed by Comet assay as
described under “Experimental Procedures.” Results
reveal that GCDA induces DNA damage in a dose-
dependent manner (Additional file 2, Figure S2A). Cells
that have accumulated DNA damage appear as fluores-
cent “comets” with tails of DNA fragmentation or
unwinding, whereas normal undamaged DNA does not
migrate far from the origin (Additional file 2, Figure
S2A). The Comet assay is able to detect SSBs, DSBs,
and apurinic/apyrimidinic (AP) sites. Because GCDA
can induce oxidative DNA damage [22,23], this may
lead to the release of free bases from DNA, generating
strand breaks with various sugar modifications and AP
sites. To test whether exposure of cells to GCDA
increases AP sites of DNA lesions, AP sites in genomic
DNA were assessed using a DNA damage quantification
(AP Site Counting) kit and analyzed using a microplate
reader with a 650-nm filter. Results indicate that treat-
ment of HepG2 cells with GCDA significantly enhances
the AP sites in genomic DNA (Additional file 2, Figure
S2B), which may partially neutralize its cell survival
activity resulting from activation of ERK/Mcl-1. Based
on the effects of GCDA on survival and AP sites of
DNA lesions, a long-term exposure of cells to GCDA
may result in an accumulation of DNA damage in living
cells leading to genetic instability and/or tumorigenesis.
Specific depletion of Mcl-1 blocks GCDA-stimulated
survival of HepG2 cells following treatment with the
chemotherapeutic drug cisplatin
To test whether Mcl-1 is a required target for GCDA-
induced survival of human HCC cells, Mcl-1 siRNA or
control siRNA was transfected into HepG2 cells. Results
indicate that cells expressing Mcl-1 siRNA displayed a >
90% reduction of Mcl-1 protein expression (Figure 6A).
Exposure of HepG2 cells without silencing of Mcl-1
prolongs survival of HepG2 cells following treatment
with cisplatin or irinotecan (Figure 6BC; column 2 vs.
column 3). By contrast, specific knockdown of Mcl-1
expression from HepG2 cells by RNAi blocks GCDA-
prolonged survival of HepG2 cells following treatment
with the chemotherapeutic drug cisplatin or irinotecan
(Figure 6BC). GCDA had no additional survival effect
on cells expressing Mcl-1 siRNA, suggesting that Mcl-1
may be a required target in GCDA-induced survival
and/or chemoresistance of HepG2 cells.
Discussion
Secretion of bile salts from the hepatocyte into bile is
essential for the excretory function of the liver. Bile salts
enter the duodenum to assist in the absorption of lipids
and fat-soluble vitamins. Bile salts are passively and/or
actively absorbed in the intestine and are transported
back to the liver via the portal circulation. Bile salts are
then taken up from the sinusoidal blood plasma by
Figure 5 GCDA reverses irinotecan-induced downregulation of
pERK and Mcl-1 and enhances survival. (A) and (B) HepG2 cells
were treated with irinotecan in the absence or presence of GCDA
for 24 h. The pERK, total ERK1/2 and Mcl-1 were analyzed by
Western blot. (C) HepG2 cells were treated with irinotecan in the
absence or presence of GCDA for 24 h. Cell viability was
determined by analyzing annexin-V binding by FACS. Data represent
the mean ± S.D. of three separate determinations.
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hepatocytes and their journey starts again [21]. Extru-
sion of bile salts from the hepatocyte is critical for liver
cell survival and prevention of hepatocyte carcinogenesis
because intracellular accumulation of bile salts not only
causes DNA damage in hepatocytes ([22,23]; Figure S2)
but also stimulates multiple cell survival and prolifera-
tion signaling pathways that may lead to tumorigenesis
[24-26]. For example, patients with severe BSEP (i.e. the
bile salt export pump) deficiency are at risk of develop-
ing HCC [21].
GCDA is one of the major bile salts in humans [32].
Bile salts and bile acids have been reported to be poten-
tial carcinogens [22,33] but the mechanism(s) involved
remains elusive. On one hand, bile salts (i.e. GCDA) can
stimulate cell survival and proliferation through
activation of PI3K/AKT and MAPK pathways [24,25].
On the other hand, bile salts can also cause oxidative
DNA damage, including accumulation of 8-hydroxy-
deoxyguanosine (8-OHdG) and DNA strand breaks
[22,23]. Our findings suggest that GCDA-induced Mcl-1
phosphorylation at T163 may occur through activation
of ERK1/2, which contributes to survival and chemore-
sistance of HCC cells (Figures. 1 and 3). Moreover, we
also discovered that exposure of cells to GCDA signifi-
cantly increases AP sites of DNA lesions (Figure S2).
Based on these findings, we propose that, in addition to
DNA damage, the mechanisms that promote cellular
survival and proliferation may also be the critical steps
in bile salt-initiated carcinogenesis.
Mcl-1 is a major antiapoptotic member of the Bcl2
family which has survival and oncogenic properties [34].
Intriguingly, Mcl-1 has been demonstrated to be a phy-
siological downstream survival substrate of MAKP/
ERK1/2 [12,18]. It is possible that the accumulated bile
salts not only induce DNA damage in hepatocytes but
also stimulate the ERK/Mcl-1 signaling pathway leading
to hepatocyte survival and/or carcinogenesis. A recent
report reveals that Mcl-1 is overexpressed in about 50%
of HCC tissues [1], suggesting that Mcl-1 may be a valu-
able oncogenic and/or therapeutic target of HCC. Our
findings reveal that GCDA potently stimulates Mcl-1
phosphorylation at the T163 site through activation of
ERK1/2 (Figures. 1, 3 and S1). It is known that constitu-
tive K-ras mutations lead to activation of a downstream
signal cascade involving Ras/Raf/MEK/ERK1/2 [35],
which may potentially enhance Mcl-1 phosphorylation.
However, only a low incidence of K-ras mutations
(~5%) could be observed in HCC patients [36,37]. By
contrast, a higher incidence of K-ras mutations in
patients with cholangiocarcinoma (i.e. 62~66%) has been
observed [38,39].
Mcl-1 is a protein with a short half-life of about 30
min~3 h [20,40]. Thus, mechanisms that enhance the
half-life of Mcl-1 are critical for its long-term survival
activity. Our findings reveal that GCDA significantly
prolongs the half-life (i.e. from 2.1 h to 8.2 h) in HepG2
cells (Figure 4). This increased Mcl-1 protein stability
may result from GCDA-induced T163 site Mcl-1 phos-
phorylation because T163 site phosphorylation has been
demonstrated to stabilize Mcl-1 in cells [18,20]. Mule
has been identified as Mcl-1 ubiquitin E3 ligase that can
induce polyubiquitination and degradation of Mcl-1
[29]. Our data indicate that GCDA can disrupt the Mcl-
1/Mule interaction in cells (Figure 4C), suggesting that
GCDA-induced T163 site phosphorylation may prevent
Mcl-1 from Mule binding and Mule-mediated polyubi-
quitination and degradation. Furthermore, GCDA-
induced Mcl-1 phosphorylation promotes Mcl-1 to
interact with the BH3-only protein Bim (Figure 2),
Figure 6 Mcl-1 is essential for GCDA-induced chemoresistance
in HepG2 cells. (A) Mcl-1 siRNA (15 nM) or control siRNA (15 nM)
was transfected into HepG2 cells using Lipofectamine 2000. After 24
h, the levels of Mcl-1 expression were analyzed by Western blot. (B)
and (C) HepG2 cells expressing Mcl-1 siRNA or control siRNA were
treated with cisplatin (30 μM) or irinotecan (40 μM) in the absence
or presence of GCDA (100 μM) for 24 h. Cell viability was
determined by analyzing annexin-V binding by FACS. Data represent
the mean ± S.D. of three separate determinations.
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which should render Mcl-1 able to more efficiently sup-
press the proapoptotic function of Bim. These findings
uncover the molecular mechanisms by which bile salts
positively regulate survival and/or enhance chemoresis-
tance of HCC cells. Since specific knockdown of Mcl-1
by RNAi blocks GCDA-induced survival of HepG2 cells
following treatment with cisplatin or irinotecan (Figure
6), our findings indicate that Mcl-1 may be a required
target for GCDA-induced survival of HCC cells.
In summary, our findings have provided strong evi-
dence that GCDA prolongs survival of HCC cells in a
mechanism that enhances the antiapoptotic function of
Mcl-1 through T163 site phosphorylation. GCDA-
induced Mcl-1 phosphorylation dissociates Mcl-1 from
its E3 ligase binding, which enhances the half-life of
Mcl-1 leading to its long-term survival function and/or
chemoresistance of HCC cells. Therefore, manipulation
of the antiapoptotic function of Mcl-1 by disrupting
T163 site phosphorylation may represent a new strategy




Mcl-1, pERK, ERK1/2, Bim and tubulin antibodies as
well as Mcl1 siRNA were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Anti-Mule antibody
was purchased from Bethyl Laboratories, INC. (Mon-
tgomery, TX). The conjugated bile salt, glycochenodeox-
yocholic acid (GCDA) was obtained from Sigma (St.
Louis, Mo). PD98059 was purchased from EMD Chemi-
cals, INC. (Gibbstown, NJ). All other reagents used were
obtained from commercial sources unless otherwise
stated.
Cell lines, metabolic labeling, immunoprecipitation and
Western blot
Hepatocellular carcinoma cell lines (HepG2, BeL-7402
and Huh7) and normal liver cell line L02 were obtained
from the Cell Bank of Type Culture Collection of Chi-
nese Academy of Sciences (Shanghai, China) and were
maintained in DMEM medium with 10% fetal bovine
serum (FBS) in a humidified cell culture incubator with
5% CO2 at 37°C. For measurement of Mcl-1 phosphory-
lation, cells were washed with phosphate-free RPMI
medium and metabolically labeled with 32P-orthopho-
sphoric acid for 60 min. After treatment with GCDA,
cells were washed with ice-cold PBS and lysed in deter-
gent buffer. Mcl-1 was immunoprecipitated and sub-
jected to 10% SDS/PAGE, transferred to a nitrocellulose
membrane and exposed to Kodak X-omat film at -80°C.
Mcl-1 phosphorylation was determined by autoradiogra-
phy. The same filter was then probed by Western blot
as described previously [20].
RNA interference
Human Mcl-1 siRNA (GAAGACCAUAAACCAA-
GAAtt) was purchased from Santa Cruz Biotechnology.
HepG2 cells were transfected with Mcl1 siRNA using
Lipofectin 2000 (Invitrogen). A control siRNA (nonho-
mologous to any known gene sequence) was used as a
negative control. The levels of Mcl1 expression were
analyzed by Western blot. Specific silencing of the tar-
geted Mcl-1 gene was confirmed by at least three inde-
pendent experiments.
Comet assay
A single-cell gel electrophoresis (Comet Assay) kit was
employed for evaluating DNA damage following the
manufacturer’s instructions (Trevigen, Inc., Gaithersburg,
MD). Comet assay is an effective method for detection of
DNA damage in cells. The principle of the assay is based
upon the ability of denatured, cleaved DNA fragments to
migrate out of the cell under the influence of an electric
field, whereas undamaged DNA migrates slower and
remains within the confines of the nucleoid when a cur-
rent is applied. After treatment of cells with GCDA, cells
in 1× PBS (Ca2+- and Mg2+-free) at 1 × 105/ml were
combined with molten LMAgarose (at 37 °C) at a ratio of
1:10 (v/v) and 75 μl immediately pipetted onto a Comet-
Slide™. After a gentle cell lysis, samples were treated
with alkali to unwind and denature the DNA and hydro-
lyze sites of damage. The samples were submitted to elec-
trophoresis, stained with a fluorescent DNA intercalating
dye (i.e. SYBR Green I nucleic acid), and visualized by a
fluorescence microscope (Zeiss).
AP Site Counting in Genomic DNA
AP sites of DNA lesions were analyzed as we described
previously [41,42]. Briefly, genomic DNA was purified
using a DNA isolation kit (Dojindo Molecular Technol-
ogies, Inc., Gaithersburg, MD). The number of AP sites
was assessed using a DNA damage quantification (AP
site counting) kit according to the manufacturer’s
instructions. Aldehyde reactive probe (ARP) reagent (N’-
aminooxymethylcarbonylhydrazino-D-biotin) can react
specifically with an aldehyde group that is the open ring
form of the AP sites. After treating DNA containing AP
sites with ARP reagent, AP sites are tagged with biotin
residues. By using an excess amount of ARP, all AP
sites can be converted to biotin-tagged AP sites. Stan-
dard ARP DNA and purified ARP-labeled sample geno-
mic DNA was fixed on a 96-well plate with DNA
binding solution. The number of AP sites in the sample
DNA was determined by the biotin-avidin-peroxidase
assay. The absorbance of the samples was analyzed
using a microplate reader with a 650-nm filter. Each
experiment was repeated three times, and the data
represent the means ± S.D. of three determinations.
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Measurement of the Mcl-1 half-life
Cycloheximide half-life assay was performed as
described [27]. Briefly, HepG2 cells were treated with
100 μg/ml cycloheximide 5 min prior to starting the
indicated time course in the absence or presence of
GCDA (100 μM). Cells were collected and lysed at the
indicated times. Mcl-1 in total cell lysate was analyzed
by Western blot. To more accurately quantify the turn-
over rate of Mcl-1, a classical 35S-methionine pulse-
chase method was also employed. Cells were metaboli-
cally labeled with 35S-methionine for 60 min. The 35S-
methionine-labeled cells were washed and incubated in
fresh methionine-replete RPMI medium 1640 in the
absence or presence of GCDA (100 μM) for various
time points up to 12 h. 35S-labeled Mcl-1 was immuno-
precipitated by using Mcl-1 antibody. The samples were
subjected to SDS/10-20% PAGE. The half-life (t1/2) of
Mcl-1 was determined by electronic autoradiography as
described [28].
Cell Viability Assay
Apoptotic and viable cells were detected using an
ApoAlert Annexin-V kit (Clontech) according to the
manufacturer’s instructions. The percentage of annexin-
Vlow (i.e. viable) or annexin-Vhigh (i.e. apoptotic) cells
was determined using the data obtained by fluores-
cence-activated cell sorter analysis as described [28].
Cell viability was also confirmed using the trypan blue
dye exclusion.
Additional material
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cells.
List of abbreviations
GCDA: glycochenodeoxycholate; HCC: hepatocellular carcinoma; ERK:
extracellular signal-regulated kinase; BH: Bcl2 homology domain; S: serine,
threonine, T; A: alanine; siRNA: small interfering RNA; RNAi: RNA interference;
AP site: apurinic/apyrimidinic site; BSEP: bile salt export pump.
Acknowledgements
We are grateful to Dr. Ulrich Maurer (University of Ulm, Ulm, Germany) for
kindly providing Mcl-1 cDNA. This work was supported by a Lotus Scholars
Program (200734), by a Flight Attendant Medical Research Institute Clinical
Innovator Award and by the Howard Hughes Medical Institute (HHMI)
Science for Life Extramural Research Award (to TW).
Author details
1National Hepatobiliary & Enteric Surgery Research Center, Department of
Surgery, Xiangya Hospital, Central South University, Changsha, Hunan
410008, P.R. China. 2Department of Radiation Oncology, Emory University
School of Medicine and Winship Cancer Institute of Emory University,
Atlanta, GA 30322, USA.
Authors’ contributions
Conceived and designed the experiments: XD, JZ and YZ; Performed
experiments: ML, TW, JZ, JD and XD; Analyzed data: XD, JZ and ML; Wrote
paper: XD, ML and JZ. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 13 October 2010 Accepted: 20 April 2011
Published: 20 April 2011
References
1. Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, Rasoul-
Rockenschaub S, Bodingbauer M, Crevenna R, Monia B, Peck-
Radosavljevic M, Wacheck V: Mcl-1 overexpression in hepatocellular
carcinoma: A potential target for antisense therapy. J Hepatol 2006,
44:151-157.
2. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003,
362:1907-1917.
3. Luo D, Cheng S, Xie H, Xie Y: Effects of Bcl2 and Bcl-XL protein levels on
chemoresistance of hepatoblastoma HepG2 cell line. Biochem Cell Biol
2000, 78:119-126.
4. Kelekar A, Thompson CB: Bcl2-family proteins: the role of the BH3
domain in apoptosis. Trends in Cell Biology 1998, 8:324-330.
5. De Biasio A, Vrana J, Zhou P, Qian L, Bieszczad C, Braley K, Domina A,
Weintraub S, Neveu J, Lane W, Craig R: N-terminal Truncation of
Antiapoptotic MCL1, but Not G2/M-induced Phosphorylation, Is
Associated with Stabilization and Abundant Expression in Tumor Cells. J
Biol Chem 2007, 282:23919-23936.
6. Chen L, Willis S, Wei A, Smith B, Fletcher J, Hinds M, Colman P, Day C,
Adams J, Huang D: Differential targeting of prosurvival Bcl2 proteins by
their BH3-only ligands allows complementary apoptotic function. Mol
Cell 2005, 17:393-403.
7. Kuwana T, Bouchier-Hayes L, Chipuk J, Bonzon C, Sullivan B, Green D,
Newmeyer D: BH3 domains of BH3-only proteins differentially regulate
Bax-mediated mitochondrial membrane permeabilization both directly
and indirectly. Mol Cell 2005, 17:525-535.
8. Pagliari L, Kuwana T, Bonzon C, Newmeyer D, Tu S, Beere H, Green D: The
multidomain proapoptotic molecules Bax and Bak are directly activated
by heat. Proc Natl Acad Sci USA 2005, 102:17975-17980.
9. Letai A: Bcl2: found bound and drugged! TRENDS in Molecular Medicine
2005, 11:442-444.
10. Hikita H, Takehara T, Shimizu S, Kodama T, Li W, Miyagi T, Hosui A, Ishida H,
Ohkawa K, Kanto T, Hiramatsu N, Yin XM, Hennighausen L, Tatsumi T,
Hayashi N: Mcl-1 and Bcl-xL cooperatively maintain integrity of
hepatocytes in developing and adult murine liver. Hepatology. 2009,
50:1217-1226.
11. Vick B, Weber A, Urbanik T, Maass T, Teufel A, Krammer PH, Opferman JT,
Schuchmann M, Galle PR, Schulze-Bergkamen H: Knockout of myeloid cell
leukemia-1 induces liver damage and increases apoptosis susceptibility
of murine hepatocytes. Hepatology 2009, 49:627-636.
12. Domina AM, Smith JH, Craig RW: Myeloid cell leukemia 1 is
phosphorylated through two distinct pathways, one associated with
extracellular signal-regulated kinase activation and the other with G2/M
accumulation or protein phosphatase 1/2A inhibition. J Biol Chem 2000,
275:21688-21694.
13. Isomoto H, Kobayashi S, Werneburg N, Bronk S, Guicciardi ME, Frank D,
Gores GJ: Interleukin 6 upregulates myeloid cell leukemia-1 expression
through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005,
42:1329-1338.
14. Schuber K, Duronio V: Distinct roles for extracellular-signal-regulated
protein kinase (ERK) mitogen-activated protein kinases and
phosphatidylinositol 3-kinase in regulation of Mcl-1 synthesis. Biochem J
Leukoc Biol 2001, 356:473-480.
15. Akgul C: Mcl-1 is a potential therapeutic target in multiple types of
cancer. Cell Mol Life Sci 2009, 66:1326-1336.
16. Bingle CD, Craig RW, Swales BM, Singleton V, Zhou P, Whyte MK: Exon
skipping in Mcl-1 results in a bcl-2 homology domain 3 only gene
product that promotes cell death. J Biol Chem 2000,
275:22136-22146.
Liao et al. Molecular Cancer 2011, 10:44
http://www.molecular-cancer.com/content/10/1/44
Page 8 of 9
17. Kobayashi S, Lee S, Meng X, Mott J, Bronk S, Werneburg N, Craig R,
Kaufmann S, Gores G: Serine 64 phosphorylation enhances the
antiapoptotic function of Mcl-1. J Biol Chem 2007, 282:18407-18417.
18. Domina A, Vrana J, Gregory M, Hann S, Craig R: Mcl-1 is phosphorylated in
the PEST region and stabilized upon ERK activation in viable cells, and
at additional sites with cytotoxic okadaic acid or taxol. Oncogene 2004,
23:5301-5315.
19. Maurer U, Charvet C, Wagman A, Dejardin E, Green D: Glycogen synthase
kinase-3 regulates mitochondrial outer membrane permeabilization and
apoptosis by destabilization of Mcl-1. Mol Cell 2006, 21:749-760.
20. Zhao J, Xin M, Wang T, Zhang Y, Deng X: Nicotine enhances the
antiapoptotic function of Mcl-1 through phosphorylation. Mol Cancer Res
2009, 7:1954-1961.
21. Stieger B: Recent insights into the function and regulation of the bile
salt export pump (ABCB11). Current Opinion in Lipidology 2009, 20:176-181.
22. Prieto AI, Ramos-Morales F, Casadesús J: Repair of DNA damage induced
by bile salts in Salmonella enterica. Genetics 2006, 174:575-584.
23. Komichi D, Tazuma S, Nishioka T, Hyogo H, Chayama K:
Glycochenodeoxycholate plays a carcinogenic role in immortalized
mouse cholangiocytes via oxidative DNA damage. Free Radic Biol Med
2005, 39:1418-1427.
24. Jaiswal K, Lopez-Guzman C, Souza R, Spechler S, Sarosi G: Bile salt
exposure increases proliferation through p38 and ERK MAPK pathways
in a non-neoplastic Barrett’s cell line. Am J Physiol Gastrointest Liver Physiol
2006, 290:G335-G342.
25. Jaiswal K, Tello V, Lopez-Guzman C, Nwariaku F, Anthony T, Sarosi G: Bile
salt exposure causes phosphatidyl-inositol-3-kinase-mediated
proliferation in a Barrett’s adenocarcinoma cell line. Surgery 2004,
136:160-168.
26. Yoon JH, Werneburg NW, Higuchi H, Canbay AE, Kaufmann SH, Akgul C,
Edwards SW, Gores GJ: Bile acids inhibit Mcl-1 protein turnover via an
epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer
Res 2002, 62:6500-6505.
27. Arnold H, Sears R: Protein phosphatase 2A regulatory subunit B56α
associates with c-Myc and negatively regulates c-Myc accumulation. Mol
Cell Biol 2008, 26:2832-2844.
28. Deng X, Gao F, Flagg T, May WS: Mono- and multi-site phosphorylation
enhances Bcl2’s anti-apoptotic function and inhibition of cell cycle entry
functions. Proc Natl Acad Sci USA 2004, 101:153-158.
29. Zhong Q, Gao W, Du F, Wang X: Mule/ARF-BP1, a BH3-only E3 ubiquitin
ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis.
Cell 2005, 121:1085-1095.
30. O’Reilly EM, Stuart KE, Sanz-Altamira PM, Schwartz GK, Steger CM,
Raeburn L, Kemeny NE, Kelsen DP, Saltz LB: A phase II study of irinotecan
in patients with advanced hepatocellular carcinoma. Cancer 2001,
91:101-105.
31. Boige V, Taïeb J, Hebbar M, Malka D, Debaere T, Hannoun L, Magherini E,
Mignard D, Poynard T, Ducreux M: Irinotecan as first-line chemotherapy in
patients with advanced hepatocellular carcinoma: a multicenter phase II
study with dose adjustment according to baseline serum bilirubin level.
Eur J Cancer 2006, 42:456-459.
32. Toke O, Monsey JD, DeKoster GT, Tochtrop GP, Tang C, Cistola DP:
Determinants of cooperativity and site selectivity in human ileal bile
acid binding protein. Biochemistry 2006, 45:727-737.
33. Bernstein H, Bernstein C, Payne CM, Dvorak K: Bile acids as endogenous
etiologic agents in gastrointestinal cancer. World J Gastroenterol 2009,
15:3329-3340.
34. Zhou P, Levy NB, Xie H, Qian L, Lee CY, Gascoyne RD, Craig RW: MCL1
transgenic mice exhibit a high incidence of B-cell lymphoma manifested
as a spectrum of histologic subtypes. Blood 2001, 97:3902-3909.
35. Low HW: Targeting Ras-RAF-ERK and its interactive pathways as novel
therapy for malignant gliomas. Curr Cancer Drug Targets 2010, 10:840-848.
36. Challen C, Guo K, Collier JD, Cavanagh D, Bassendine MF: Infrequent point
mutations in codons 12 and 16 of ras oncogenes in human
hepatocellular carcinomas. J Hepatol 1992, 14:342-346.
37. Tada M, Omata M, Ohto M: Analysis of ras gene mutations in human
hepatic malignant tumor by polymerase chain reaction and direct
sequencing. Cancer Res 1990, 50:1121-1124.
38. Tada M, Omata M, Ohto M: Detection of ras gene mutations of primary
hepatic malignant tumors by polymerase chain reaction and direct
sequencing. Nippon Shokakibyo Gakkai Zasshi 1990, 87:811-815.
39. Stork P, Loda M, Bosari S, Wiley B, Poppenhusen K, Wolfe H: Detection of
K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic
mismatched polymerase chain reaction. Oncogene 1991, 6:857-862.
40. Liu H, Peng H, Cheng Y, Yuan H, Yang Y: Stabilization and enhancement
of the antiapoptotic activity of Mcl-1 by TCTP. Mol Cell Biol 2005,
25:3117-3126.
41. Jin Z, May WS, Gao F, Flagg T, Deng X: Bcl2 suppresses DNA repair by
enhancing c-Myc transcriptional Activity. J Biol Chem 2006,
281:14446-14456.
42. Zhao J, Gao F, Zhang Y, Wei K, Liu Y, Deng X: Bcl2 inhibits abasic site
repair by down-regulating APE1 endonuclease activity. J Biol Chem 2008,
283:9925-9932.
doi:10.1186/1476-4598-10-44
Cite this article as: Liao et al.: Role of bile salt in regulating Mcl-1
phosphorylation and chemoresistance in hepatocellular carcinoma cells.
Molecular Cancer 2011 10:44.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Liao et al. Molecular Cancer 2011, 10:44
http://www.molecular-cancer.com/content/10/1/44
Page 9 of 9
